Effects of Parathyroidectomy Versus Observation on the Development of Vertebral Fractures in Mild Primary Hyperparathyroidism
Overview
Authors
Affiliations
Context: Mild primary hyperparathyroidism (PHPT) is a common disease especially in middle-aged and elderly women. The diagnosis is frequently made incidentally and treatment strategies are widely discussed.
Objective: To study the effect of parathyroidectomy (PTX) compared with observation (OBS) on biochemistry, safety, bone mineral density (BMD), and new fractures.
Design: Prospective, randomized controlled study (SIPH study), with a 5-year follow-up.
Setting: The study was conducted at multicenter, tertiary referral centers.
Patients: Of 191 randomized patients with mild PHPT, biochemical data were available for 145 patients after 5 years, with a mean age at inclusion of 62.8 years (OBS group, 9 males) and 62.1 years (PTX group, 10 males).
Intervention: Parathyroidectomy vs observation.
Main Outcome Measures: Biochemistry, BMD, and new radiographic vertebral fractures.
Results: Serum-calcium and PTH-levels normalized after surgery and did not deteriorate by observation. BMD Z-scores were normal at inclusion in the lumbar spine (LS) and femoral neck (FN). For LS, BMD Z-scores were stable for 5 years with observation, but decreased in FN (P < .02). After surgery, BMD Z-scores increased significantly in both compartments (P < .02 for both), with a highly significant treatment effect of surgery compared to observation (P < .001). During follow-up, five new clinically unrecognized vertebral fractures were found in 5 females, all in the OBS group (P = .058).
Conclusion: Even though new vertebral fractures occurred only in the observation group, the frequency was not significantly different from the surgery group. Longer follow-up is needed before firm conclusions can be drawn about the long-term safety of observation, as opposed to surgery.
Skeletal phenotypes in postmenopausal women affected by primary hyperparathyroidism.
Corbetta S, Gianotti L, Castellano E, Carrara S, Raineri F, Munari E Front Endocrinol (Lausanne). 2024; 15:1475147.
PMID: 39539933 PMC: 11558525. DOI: 10.3389/fendo.2024.1475147.
Lin T, Lin S, Yeh K World J Clin Cases. 2024; 12(25):5761-5768.
PMID: 39247751 PMC: 11263049. DOI: 10.12998/wjcc.v12.i25.5761.
Han Z, Xue Y, Liang L, Xie J, Zhou Z Quant Imaging Med Surg. 2024; 14(6):3828-3836.
PMID: 38846300 PMC: 11151268. DOI: 10.21037/qims-23-1719.
Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.
Vescini F, Borretta G, Chiodini I, Boniardi M, Carotti M, Castellano E Endocr Metab Immune Disord Drug Targets. 2024; 24(8):991-1006.
PMID: 38644730 PMC: 11165713. DOI: 10.2174/0118715303260423231122111705.
Wang X, Shi G, Li G, Tang G Int Urol Nephrol. 2023; 56(4):1217-1225.
PMID: 38038823 DOI: 10.1007/s11255-023-03882-w.